A New Weapon In Generic Drug Companies' Arsenal

Law360, New York (April 19, 2013, 12:02 PM EDT) -- Generic drug companies have seized on the U.S. Patent and Trademark Office's inter partes review proceeding as a new weapon in their assault on patents protecting branded drug products. Since the post-grant review provisions of the America Invents Act took effect on Sept. 16, 2012, two major players in the generic drug industry, Apotex Inc. and Ranbaxy Laboratories Ltd., have filed inter partes review petitions challenging the validity of patents listed in the U.S. Food and Drug Administration's Orange Book. Brand-name drug companies, already facing stiff competition from generics,[1] now face the prospect of fighting a two-front patent war — in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!